ABSTRACT
Background: Hidradenitis Suppurativa (HS) is a chronic, relapsing, inflammatory skin condition which is physically, psychologically and socially disabling and often affects a patient's quality of life (QOL). There are numerous QOL tools used in dermatology. However, assessment of QOL in patients with HS is difficult due to the inability of generic QOL tools to specifically capture QOL in patients with HS. Numerous HS-specific QOL tools have been developed in recent years. It is important to identify evidence on full psychometric evaluation of these tools. Objectives: There has been a gradual increase in the use of generic and disease-specific QOL tools in the last few decades. The aim of this scoping review (SR) is to evaluate the most widely used generic QOL tools and HS-specific QOL tools to identify the psychometric evaluation of such tools. Methods: Design: An SR guided by Joanna Briggs Institute manual and Arskey O'Malley framework guidelines. Data extraction included the studies available on full psychometric evaluation of the most widely used dermatology generic QOL tools in HS and HS-specific QOL tools. Results: Ten papers were included in the review, eight papers demonstrated HS-specific QOL assessment tools. The psychometric properties of these tools were underpinned by reliability, validity and sensitivity measurement. Six disease-specific tools were identified in this SR. However, they all lack full psychometric evaluation. Conclusion: This review indicates that an extensive research in the field of QOL tools for HS is much needed. It is crucial to develop user-friendly and validate disease-specific tools to measure the real impact of disease on patients QOL. QOL instruments can evaluate the impact on life of an HS patient, thus helping improve intervention and management of disease. There is a necessity for more research into existing HS-specific QOL tools and they should be widely tested and fully validated.
Subject(s)
Skin Neoplasms , Sunburn , Male , Humans , Ireland , Sunlight , Sunscreening Agents , Skin Neoplasms/drug therapy , Protective Clothing , Health Knowledge, Attitudes, PracticeABSTRACT
Ireland has the highest per capita users of fake tan in the world. We have very often seen the effect of this in our Dermatology clinics. We analysed the number of patients presenting with fake tan to our pigmented lesion clinics, which results in unnecessary rescheduling, further patient anxiety and delay in diagnoses, as well as increasing patient waiting lists. We have included images of the effect of fake tan on dermoscopy and in vivo confocal microscopy - complicating our ability to diagnose. We implemented a change in our practice, which we hope will improve this dilemma.
Subject(s)
Dermatology , Skin Neoplasms , Humans , Skin Neoplasms/pathology , IrelandSubject(s)
Prurigo , Administration, Cutaneous , Humans , Prurigo/complications , Prurigo/drug therapy , SkinSubject(s)
COVID-19 , Scabies , Humans , Ivermectin , Pandemics , SARS-CoV-2 , Scabies/complicationsABSTRACT
Secukinumab is a novel anti-interleukin-17A agent that has achieved a 75% decrease from baseline in Psoriasis Area and Severity Index (PASI 75) in 77-81% of patients treated in clinical trials Langley et al. (N Engl J Med 371:326-338, 2014). There is limited data on the use of secukinumab outside of clinical trials. We provide real-world data on the efficacy and safety of secukinumab in patients with severe psoriasis attending an outpatient dermatology service. In our retrospective review, we demonstrate (PASI 75) a response rate of 47% in patients previously treated with multiple systemic and biologics. Our efficacy is comparable to that seen in the Signature study who examined similar populations. Response was maintained at follow-up of almost 1 year with acceptable safety data. Patients with psoriatic arthritis were more likely to remain on secukinumab than those without at last clinic follow-up.
